News & Updates

In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.

In patients with chronic dependence on oral corticosteroids (OCS) for severe asthma, long-term exposure to dupilumab supports sustained reduction in OCS dosage and improvement in clinical outcomes for up to 96 weeks, according to an analysis of the phase III LIBERTY ASTHMA TRAVERSE study.

In individuals with immune-mediated inflammatory diseases (IMIDs*), a 2-week interruption in methotrexate (MTX) treatment led to enhanced COVID-19 booster vaccine response compared with those who continued with MTX treatment, according to findings from the VROOM** study.

A large global study of patients with severe COVID-19 admitted to the intensive care unit (ICU) has shown a 14 percent prevalence of haemorrhagic, coagulopathic, and thrombotic (HECTOR) complications in these patients, with mortality risk increased in those with haemorrhagic complications. 

Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.

Patients with ST-segment elevation myocardial infarction (STEMI) are more likely to develop a coronary collateral vessel (CCV) in the presence of obstructive sleep apnoea (OSA), according to a study.

Surrogates of SARS-CoV-2* – a lipid enveloped RNA bacteriophage (Phi6) and two animal coronaviruses (CoVs; MHV and TGEV**) – survived in cold-storage temperatures for 30 days, a study finds, highlighting the risk of viral survival on food products and potential transmission on humans upon consumption.